New Keytruda Approval Rekindles An Old Debate

Approval for first-line BRAF+ patients puts Merck's Keytruda ahead of Bristol's Opdivo in melanoma, and in line to take share from BRAF/MEK combos, which are currently dominant in this patient population. Interactive timeline gives visual overview of immunotherapy approvals in key markets.